Sinovac Biotech (SVA)
NASDAQ:SVA
Want to see SVA full AI Analyst Report?
Top Page
Rating:―N/A
Price Target:―
Action:N/A
Date:―
No summary available
Positive Factors
Strong Balance Sheet
A strong balance sheet with high liquidity and low debt provides financial flexibility and stability, allowing the company to weather economic fluctuations and invest in growth opportunities.
Negative Factors
Revenue Decline
A significant decline in revenue indicates challenges in maintaining market demand and competitive positioning, which could impact long-term financial performance and growth prospects.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Balance Sheet
A strong balance sheet with high liquidity and low debt provides financial flexibility and stability, allowing the company to weather economic fluctuations and invest in growth opportunities.
Read all positive factors
Sinovac Biotech (SVA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$460.27M
Dividend Yield0%
Average Volume (3M)8.23K
Price to Earnings (P/E)6.0
Beta (1Y)N/A
Revenue Growth-13.72%
EPS GrowthN/A
CountryUS
Employees1,959
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.00
Shares Outstanding71,860,700
10 Day Avg. Volume8,227
30 Day Avg. Volume8,227
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.07
Price to Sales (P/S)1.44
P/FCF Ratio-15.46
Enterprise Value/Market Cap-1.10
Enterprise Value/Revenue-1.13
Enterprise Value/Gross Profit-1.95
Enterprise Value/Ebitda83.96
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Sinovac Biotech Business Overview & Revenue Model
Company Description
Sinovac Biotech Ltd., a biopharmaceutical company, focuses in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes v...
How the Company Makes Money
Sinovac Biotech generates revenue primarily through the sale of vaccines to both government and private sector clients. The company's key revenue streams include domestic sales within China and international sales to countries around the world. Si...
Sinovac Biotech Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Mar 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 448.27M | 1.49B | 19.37B | 510.62M | 246.05M |
| Gross Profit | 266.75M | 808.30M | 18.30B | 443.44M | 213.58M |
| EBITDA | -6.03M | 183.10M | 17.65B | 221.76M | 76.05M |
| Net Income | -99.92M | 113.87M | 8.47B | 110.37M | 44.93M |
Balance Sheet | |||||
| Total Assets | 13.66B | 14.11B | 16.75B | 1.90B | 452.30M |
| Cash, Cash Equivalents and Short-Term Investments | 11.22B | 11.31B | 13.42B | 1.18B | 202.99M |
| Total Debt | 298.98M | 74.67M | 144.91M | 136.39M | 20.27M |
| Total Liabilities | 1.64B | 1.40B | 2.87B | 781.20M | 100.10M |
| Stockholders Equity | 8.71B | 8.92B | 9.33B | 746.47M | 294.02M |
Cash Flow | |||||
| Free Cash Flow | -41.69M | -1.17B | 14.63B | 351.66M | 28.45M |
| Operating Cash Flow | 104.00M | -770.75M | 15.35B | 479.31M | 39.07M |
| Investing Cash Flow | -2.93B | -5.76B | -3.02B | -204.76M | -42.45M |
| Financing Cash Flow | -76.06M | -241.40M | -1.90B | 592.57M | 1.74M |
Sinovac Biotech Risk Analysis
Sinovac Biotech disclosed 71 risk factors in its most recent earnings report. Sinovac Biotech reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 2 New Risks
1.
The Rights Agreement and certain provisions of Sinovac Antigua's By-laws may discourage a change of control. Q4, 2023
2.
We may be required to complete filing procedures with CSRC in connection with our future offerings, and we cannot predict whether we will be able to complete such filing on a timely manner, or at all. Q4, 2023
Sinovac Biotech Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
| ― | $460.27M | 6.03 | ― | 0.00% | -13.72% | ― | |
50 Neutral | $776.48M | >-0.01 | 87.31% | ― | ― | -1004.74% | |
49 Neutral | $167.45M | -1.67 | -117.86% | ― | -20.31% | -23.75% | |
48 Neutral | $453.62M | -7.56 | -9999.00% | ― | -1.26% | -23.97% | |
46 Neutral | $247.77M | -4.18 | 85.78% | ― | 20.08% | 14.06% |
* General Sector Average
SVA
Sinovac Biotech
6.47
0.00
0.00%
OCGN
Ocugen
1.34
0.41
44.09%
KRRO
Korro Bio
11.61
-1.21
-9.44%
FHTX
Foghorn Therapeutics
4.22
0.17
4.20%
VOR
Vor Biopharma
14.33
10.86
312.97%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―